What type of medicine does fostatinib/fotantinib belong to?

Fostamatinib is an oral small molecule tyrosine kinase inhibitor that mainly targets spleen tyrosine kinase (SYK) and is a targeted therapy drug in the field of modern hematology. SYK is an important enzyme in immune cell signaling and plays a key role in antibody-mediated immune responses. In patients with chronic immune thrombocytopenia (ITP), abnormal immune responses in the body can lead to platelet destruction and abnormally enhanced activity of the SYK signaling pathway. By inhibiting SYK activity, fostatinib can block antibody-mediated platelet destruction, increase platelet count, and thereby reduce the risk of bleeding.

Compared with traditional immunosuppressants such as glucocorticoids or intravenous immune globulin, fostatinib has the advantages of oral convenience and clear targeting effect. It can not only be used as a monotherapy, but can also be used in combination with other platelet production promoters to provide new treatment strategies for patients with refractory ITP. The mechanism of action of fostatinib reflects the trend of modern hematology treatment shifting from broad-spectrum inhibition to precise targeting. By selectively intervening in abnormal immune signals, it achieves effective control of platelet levels without significantly affecting other immune functions. This precise action makes it relatively safe in long-term treatment, reducing the risk of suppressing the systemic immune system.

Fostatinib is mainly used in clinical trials to treat adult patients with chronic ITP who have poor response or relapse to traditional treatments.Its potential efficacy in other autoimmune blood diseases is also being explored in the research phase. Its adverse reactions are relatively controllable and commonly include hypertension, abnormal liver function and mild gastrointestinal symptoms. Hematological indicators and liver function need to be monitored regularly during use.

Overall, the emergence of fostatinib provides a reliable new oral treatment option for refractory immune thrombocytopenia, represents a new direction in targeted blood disease management, and also provides patients with more flexible and personalized treatment options.

Reference materials:https://go.drugbank.com/drugs/DB12010